02 November 2023

via Zoom

NICE has received an appeal against the Final Draft Guidance on the above technology from the following organisations:

  • GSK
  • Myeloma UK

The appeal hearing originally scheduled for 2 November has been cancelled as the Final Draft Guidance has been withdrawn and the appraisal has been paused.

Please check the topic guidance page for further information and next steps.